drugset
drugset / Trial / NCT06933394

Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma

NCT06933394 ↗

Phase 2 Recruiting 92 enrolled Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NaSingle-groupOpen-labelTreatment

Summary

This prospective, single-arm, multi-center clinical trial aims to explore and evaluate the efficacy and safety of the combination therapy involving arsenic trioxide, MAPK inhibitors, and chemotherapy for stage 4/M neuroblastoma.

Timeline

Start
2025-05-01
Primary completion
2031-05-01
Completion
2031-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Trametinib Small molecule 0.012 mg/kg Oral
Subject Trametinib Small molecule 0.016 mg/kg Oral
Subject Trametinib Small molecule 0.018 mg/kg Oral
Subject Trametinib Small molecule 0.024 mg/kg Oral
Subject Trametinib Small molecule 0.025 mg/kg Oral
Subject Trametinib Small molecule 0.032 mg/kg Oral
Subject arsenic trioxide Small molecule 0.18 mg/kg Intravenous
Background Cisplatin Other / unclassified 50 mg/m2 —
Background Cyclophosphamide Other / unclassified 1.2 g —
Background Etoposide Small molecule 200 mg/m2 —
Background Pirarubicin Small molecule 25 mg/m2 —
Background Topotecan Small molecule 2 mg/m2 —
Background Vincristine Small molecule 0.022 mg/kg —
Background Vincristine Small molecule 0.67 mg/m2 —

Indications

neuroblastoma